## Abstract ## Objective To extend the knowledge of course of improvement in patients with major depressive disorder (MDD), social anxiety disorder (SAD) or generalised anxiety disorder (GAD) participating in randomised placeboβcontrolled trials (RCTs) and to infer the optimal duration of initial
β¦ LIBER β¦
Qualitative changes in symptomatology as an effect of treatment with escitalopram in generalized anxiety disorder and major depressive disorder
β Scribed by Yves Lecrubier; Ornah T. Dolberg; Henning F. Andersen; Emmanuelle Weiller
- Publisher
- Springer-Verlag
- Year
- 2007
- Tongue
- English
- Weight
- 282 KB
- Volume
- 258
- Category
- Article
- ISSN
- 1433-8491
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
How long should a trial of escitalopram
β
David S. Baldwin; Dan J. Stein; Ornah T. Dolberg; Borwin Bandelow
π
Article
π
2009
π
John Wiley and Sons
π
English
β 130 KB
π 2 views
Escitalopram in the treatment of major d
β
Pratap Chokka; Mark Legault
π
Article
π
2008
π
John Wiley and Sons
π
English
β 131 KB
π 2 views
Testing anxious depression as a predicto
β
George I. Papakostas; Klaus Larsen
π
Article
π
2010
π
Springer-Verlag
π
English
β 257 KB
Effectiveness of mindfulness-based cogni
β
Yong Woo Kim; Sang-Hyuk Lee; Tae Kyou Choi; Shin Young Suh; Borah Kim; Chan Mo K
π
Article
π
2009
π
John Wiley and Sons
π
English
β 91 KB
π 2 views
Effectiveness and tolerability of citalo
β
Shella Schirman; Sefi Kronenberg; Alan Apter; David Brent; Nadine Melhem; Nimrod
π
Article
π
2009
π
Springer
π
English
β 176 KB
Effectiveness and tolerability of paroxe
β
Chi-Un Pae; Won-Myong Bahk; Duk-In Jon; Sang-Yeol Lee; Bo-Hyun Yoon; Kyung Joon
π
Article
π
2007
π
John Wiley and Sons
π
English
β 127 KB
π 2 views
## Abstract ## Objectives This study evaluated the effectiveness and tolerability of paroxetine controlled release (CR) for the treatment of Korean patients with major depressive disorder (MDD) in a naturalistic treatment setting. ## Methods One hundred and ninety patients with MDD were enrolled